Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome

Next Previous
X
Search
Trial Profile

HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ION 582 (Primary)
  • Indications Angelman syndrome
  • Focus Adverse reactions; First in man
  • Acronyms HALOS
  • Sponsors Ionis Pharmaceuticals

    • Most Recent Events

    • 22 Jul 2024 According to an Ionis Pharmaceuticals Media Release, detailed results will be presented in a company webcast today and at the 2024 Angelman Syndrome Foundation (ASF) Family Conference in Sandusky, Ohio on July 24, 2024.
    • 22 Jul 2024 Positive results from the completed multiple ascending dose (MAD) portion, presented in an Ionis Pharmaceuticals Media Release.
    • 08 Jul 2024 According to an Ionis Pharmaceuticals media release, the company will host live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Also results from this study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top